Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Replacement Volume and AST-120 (Kremezin) on Protein-bound Toxins, Oxidative Stress and MicroInflammation in Patients Receiving Online Hemodiafiltration

NCT01458652 is registered in ClinicalTrials.gov with Tungs' Taichung Metroharbour Hospital as lead sponsor.

NCT NCT01458652
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01458652 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Replacement Volume and AST-120 (Kremezin) on Protein-bound Toxins, Oxidative Stress and MicroInflammation in Patients Receiving Online Hemodiafiltration
Lead sponsor
Tungs' Taichung Metroharbour Hospital
Phase
Phase 4
Overall status
Completed
Start date
January 31, 2011
Completion date
October 31, 2013
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

loss of solute clearance